Sarcopenia in Chronic Kidney Disease: A Scoping Review of Prevalence, Risk Factors, Association with Outcomes, and Treatment
Autor: | Varvara Chatzipetrou, Marie-Josée Bégin, Andrea Trombetti, Mélany Hars |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
Sarcopenia medicine.medical_specialty Endocrinology Diabetes and Metabolism Population Psychological intervention Review Article Disease law.invention Endocrinology Randomized controlled trial Risk Factors law Chronic kidney disease Internal medicine Prevalence medicine Humans Orthopedics and Sports Medicine Renal Insufficiency Chronic Stage (cooking) Muscle Skeletal education Randomized Controlled Trials as Topic education.field_of_study business.industry Physical performances musculoskeletal system medicine.disease Malnutrition Muscle business human activities Kidney disease |
Zdroj: | Calcified Tissue International |
ISSN: | 1432-0827 0171-967X |
DOI: | 10.1007/s00223-021-00898-1 |
Popis: | Sarcopenia, a condition characterized by loss of skeletal muscle mass and function, has important clinical ramifications. We aimed to map the existing literature about prevalence, risk factors, associated adverse outcomes, and treatment of sarcopenia in individuals with chronic kidney disease (CKD). A scoping review of the literature was conducted to identify relevant articles published from databases’ inception to September 2019. Individuals with CKD, regardless of their disease stage and their comorbidities, were included. Only studies with sarcopenia diagnosed using both muscle mass and function, based on published consensus definitions, were included. For studies on treatment, only randomized controlled trials with at least one sarcopenia parameter as an outcome were included. Our search yielded 1318 articles, of which 60 from were eligible for this review. The prevalence of sarcopenia ranged from 4 to 42% according to the definition used, population studied, and the disease stage. Several risk factors for sarcopenia were identified including age, male gender, low BMI, malnutrition, and high inflammatory status. Sarcopenia was found to be associated with several adverse outcomes, including disabilities, hospitalizations, and mortality. In CKD subjects, several therapeutic interventions have been assessed in randomized controlled trial with a muscle mass, strength, or function endpoint, however, studies focusing on sarcopenic CKD individuals are lacking. The key interventions in the prevention and treatment of sarcopenia in CKD seem to be aerobic and resistance exercises along with nutritional interventions. Whether these interventions are effective to treat sarcopenia and prevent clinical consequences in this population remains to be fully determined. Supplementary Information The online version contains supplementary material available at 10.1007/s00223-021-00898-1. |
Databáze: | OpenAIRE |
Externí odkaz: |